Literature DB >> 6124638

Synthesis and cardiovascular activity of a new series of cyclohexylaralkylamine derivatives related to perhexiline.

G Leclerc, N Decker, J Schwartz.   

Abstract

A series of 24 cyclohexylaralkylamine derivatives related to perhexiline has been synthesized and screened for cardiovascular activity. All the compounds contained an exocyclic amine which was substituted either by an alkyl, cycloalkyl, or aralkyl group. In the hope of further reducing toxicity, the synthesis of p-tolyl- and p-hydroxyphenyl derivatives 23 and 24 was undertaken. The effect of separating the cyclohexylamine moiety with respect to the aromatic nucleus has been systematically examined. The pharmacological investigations were directed to a search for compounds having an activity better than perhexiline according to the following order of criteria: (1) alpha-adrenolytic activity; (2) increase of coronary blood flow; (3) calcium antagonism. Several compounds were more potent and exhibited lower toxicity than perhexiline. Further detailed pharmacological investigations (tension time index and decreased cardiac work) have led to the selection of N,2-dicyclohexyl-2-phenethylamine (3) for clinical trials, which are now under way.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6124638     DOI: 10.1021/jm00348a019

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Effects of some antianginal and vasodilating drugs on sodium influx and on the binding of 3H-batrachotoxinin-A 20-alpha-benzoate and 3H-tetracaine.

Authors:  J Velly; M Grima; G Marciniak; M O Spach; J Schwartz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-02       Impact factor: 3.000

2.  Anti-anginal arylalkylamines and sodium channels: [3H]-batrachotoxinin-A 20-alpha-benzoate and [3H]-tetracaine binding.

Authors:  M Grima; J Schwartz; M O Spach; J Velly
Journal:  Br J Pharmacol       Date:  1986-12       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.